Apyx Medical Corporation

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As described under Item 5.07 of this Current Report on Form 8-K, Apyx Medical Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which the Company’s stockholders approved the adoption of the Company’s 2026 Share Incentive Plan (the “2026 Plan”). A summary of the 2026 Plan is contained, under the heading “Approval of the 2026 Share Incentive Plan”, in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on June 26, 2026 (the “Proxy Statement”). The foregoing description of the 2026 Plan is qualified in its entirety by reference to the full text of the 2026 Plan that is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders. On August 6, 2026, the following proposals were submitted to the stockholders of the Company at its Annual Meeting: (1) the election of five (5) directors; (2) the ratification of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026; (3) the approval of a non-binding advisory resolution supporting the compensation of the Company’s named executive officers; and (4) the approval of the Company’s 2026 Share Incentive Plan. The proposals are described in more detail in the Proxy Statement. The following are the final voting results for each proposal: Proposal The Company’s 1: stockholders elected each of the following five (5) directors to serve on the Board of Directors of the Company until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, by the following vote: Name Number Number Number Broker of Votes of Votes of Votes Cast in Favor Cast Against Abstained Non-Votes ─────────────────────────────────────────────────────────────────────────────────────────────── Stavros G. Vizirgianakis 18,051,294 4,083,005 84,359 7,677,267 Charles D. Goodwin 21,338,164 788,416 92,078 7,677,267 Lawrence J. Waldman 21,332,747 718,782 167,129 7,677,267 Minnie Baylor-Henry 15,400,914 6,650,608 167,136 7,677,267 Wendy Levine 15,395,258 6,656,271 167,129 7,677,267 Proposal The 2: Company’s stockholders ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, by the following vote: ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Number Number Number Broker of Votes of Votes of Votes Cast in Favor Cast Against Abstained Non-Votes ───────────────────────────────────────────────────────────────── 29,814,618 31,610 49,697 - Proposal The 3: Company’s stockholders approved a non-binding advisory resolution supporting the compensation of the Company’s named executive officers, by the following vote: Number Number Number Broker of Votes of Votes of Votes Cast in Favor Cast Against Abstained Non-Votes ───────────────────────────────────────────────────────────────── 21,458,554 669,298 90,806 7,677,267 Proposal The 4: Company’s stockholders approved the Company’s 2026 Share Incentive Plan, by the following vote: Number Number Number Broker of Votes of Votes of Votes Cast in Favor Cast Against Abstained Non-Votes ───────────────────────────────────────────────────────────────── 16,186,776 2,755,882 3,276,000 7,677,267